Valuation: Prothena Corporation plc

Market Cap 435M 389M 358M 325M 607M 41.29B 618M 4.27B 1.71B 21.72B 1.63B 1.6B 68.49B P/E 2026 *
71.4x
P/E 2027 * -8.27x
Enterprise Value 435M 389M 358M 325M 607M 41.29B 618M 4.27B 1.71B 21.72B 1.63B 1.6B 68.49B EV / Sales 2026 *
5.26x
EV / Sales 2027 * 20.7x
Free-Float
77.15%
Yield 2026 *
-
Yield 2027 * -
1 day-4.62%
1 week+3.29%
Current month+1.07%
1 month+1.07%
3 months+0.71%
6 months-23.42%
Current year-11.31%
1 week 8.21
Extreme 8.21
9.26
1 month 7.8
Extreme 7.8
9.3
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
41.54
5 years 4.32
Extreme 4.32
79.65
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Buy 10,000 0.0195%
8/10/26 Buy 90,000 0.1753%
2/10/26 Buy 100,000 0.1948%
Change 5-day change 1-year change 3-year change Capi.($)
-4.62%+3.29%-19.18%-76.12% 435M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.16%+7.11%+41.16%+178.08% 39.48B
Weighted average by Cap. +0.17%+5.44%+48.43%+185.84%

Financials

2026 *2027 *
Net sales 82.7M 74.07M 68.13M 61.73M 115M 7.85B 118M 812M 326M 4.13B 310M 304M 13.03B 21.04M 18.84M 17.33M 15.7M 29.35M 2B 29.9M 207M 82.96M 1.05B 78.94M 77.27M 3.31B
Net income 6.62M 5.93M 5.45M 4.94M 9.24M 629M 9.41M 65.04M 26.11M 331M 24.85M 24.32M 1.04B -54.06M -48.42M -44.54M -40.36M -75.43M -5.13B -76.85M -531M -213M -2.7B -203M -199M -8.52B
Net Debt - -
Projected Income Statement - Annual - Prothena Corporation plc
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
30/10/26 US$8.470 -4.62% 452,298
29/10/26 US$8.880 -2.42% 370,069
28/10/26 US$9.100 +3.29% 751,998
27/10/26 US$8.810 +4.88% 654,353
26/10/26 US$8.400 +2.44% 594,545
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Prothena Corporation plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.470USD
Average target price
21.40USD
Spread / Average Target
+152.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Prothena Corporation plc
  1. Stock Market
  2. Stocks
  3. PRTA Stock